Longtime CEO Doug Ingram will step down as Sarepta Therapeutics navigates declining sales of its flagship gene therapy Elevidys, regulatory setbacks, and mounting competition, marking the end of a transformative yet turbulent era for the Duchenne muscular dystrophy specialist.
Universal Corporation (UVV) reported its fiscal 2026 third-quarter results, showcasing resilience in its core tobacco operations while strategically navigating headwinds in its growing ingredients segment. The company highlighted a refinanced credit facility and new CFO appointment as it manages the shift from a leaf tobacco undersupply to an oversupply environment.
Fox News host Laura Ingraham challenged Rep. Pat Fallon's call for deploying U.S. ground troops to Iran to ensure a satisfactory end to the conflict, arguing the situation is far more complex and cautioning against mission creep.
Despite a challenging quarter for the BBH Select Mid Cap ETF, Darling Ingredients emerged as a standout performer, buoyed by robust sales growth and its pivotal role in the circular bioeconomy. The company's latest results highlight a market increasingly rewarding sustainable business models.
Investment firm Palo Duro Investment Partners has established a significant new position in sustainable ingredients leader Darling Ingredients, signaling strong institutional confidence in the waste-to-value sector.
William Ingram received a 30-to-64-year prison sentence for the killing of his 82-year-old mother, Dolores, whose body was discovered concealed beneath a disturbing cache of household debris, narcotics, and over $53,000.
Fueled by the sustained strength of INGREZZA and a stellar launch for CRENESSITY, Neurocrine Biosciences reports robust 2025 growth and outlines a data-rich pipeline poised to redefine treatment in neuropsychiatry and endocrinology.
Fox News host Laura Ingraham, a longtime Trump ally, publicly questioned whether the President was fully briefed on the risks of the ongoing military engagement with Iran, as oil prices surge and plans for a high-stakes uranium extraction mission emerge.
Shares of Alto Ingredients (NASDAQ: ALTO) have surged 70% over the past year, dramatically outpacing the broader market. This impressive rally comes despite a recent decline in company revenue and a challenging three-year performance, raising questions about the drivers behind the investor optimism and the stock's future trajectory.
Darling Ingredients Inc. closed 2025 with robust EBITDA growth and margin expansion, led by its core ingredients business. Despite challenges in renewable fuels, the company is optimistic for 2026, citing favorable policy shifts and a strategic acquisition in Brazil to bolster its global footprint.
Analysts at Morgan Stanley reiterate that Ingrezza remains the central driver of value for Neurocrine Biosciences, following robust quarterly earnings and raised long-term sales guidance for the flagship drug.
All eyes are on Darling Ingredients (DAR) as it prepares to release its quarterly results. With the stock surging ahead of the report, analysts and investors are weighing whether the company can meet expectations in a volatile agricultural ingredients market.
French fragrance and flavor leader Robertet (ENXTPA:RBT) has taken an equity stake in Aethera Biotech, expanding their partnership and marking a decisive push into biotechnology for cosmetic actives. The move aims to develop next-generation natural ingredients and could redefine the company's growth trajectory in the competitive beauty market.
Fox News host Laura Ingraham challenged Senator Ted Cruz on the appropriateness of colleague Lindsey Graham's undisclosed meetings with Israeli PM Netanyahu ahead of U.S.-led strikes on Iran, as the human cost of the conflict mounts.
Shares of IT distribution giant Ingram Micro Holding (INGM) have posted significant gains in recent months, outpacing broader market trends without an obvious catalyst. This rally has investors and analysts debating whether the stock's momentum signals untapped value or has pushed it beyond its fair price.
Sarepta Therapeutics CEO Douglas Ingram will step down by the end of 2026, the company announced, marking the end of a tenure defined by both groundbreaking approvals and significant safety challenges for its flagship gene therapy, Elevidys.
The Trump administration's new 15% global tariff, enacted under the Trade Act of 1974, introduces fresh cost and complexity for global technology distributors. For Ingram Micro, the move pressures hardware margins and working capital, even as its strategic pivot towards AI and cloud platforms seeks to offset traditional product economics.
Neurocrine Biosciences has launched a mid-stage trial for a new VMAT2 inhibitor, aiming to build on its legacy in movement disorders. While the long-term pipeline holds promise, analysts say the company's near-term fortunes remain tightly hitched to its flagship product.
Fox News hosts have moved to justify President Trump's abrupt firing of Attorney General Pam Bondi, citing mounting frustrations over her handling of the Epstein documents release and other controversies, as the administration reshuffles its legal team.
Strong quarterly results and a strategic move into higher-value collagen have reignited the investment case for Darling Ingredients, though concerns over renewable fuel economics and leverage persist.
